Analysis of Circulating Vascular Endothelial Growth Factor and Its Soluble Receptors in Patients with Different Forms of Chronic Urticaria

Table 2

Plasma concentration of VEGF, VEGF-R1, and VEGF-R2 and number of platelets in chronic urticaria patients and healthy subjects.

Analysed parameters (unit)	Chronic urticaria				Control; ( = 34)
	CSU/ASST(−); ( = 40)	CSU/ASST(+); = 26)	CSU/ASST(+)/; Hashimoto; ( = 13)	DPU; ( = 12)
	Median; (IQR)	Median; (IQR)	Median; (IQR)	Median; (IQR)	Median; (IQR)
VEGF; (pg/mL)	19.80; (7.65–27.05)	23.35; (9.8–26.8)	= 0.0003; 37.7; (33.45–42.55)	= 0.0118; 29.85; (21.3–41.5)	18.3; (0–24.5)
sVEGF-R1; (pg/mL)	36.50; (27.35–46)	41.00; (34.1–46.80)	47.50; (36.225–50.45)	32.05; (27.05–42.25)	39.40; (26.6–24.2)
sVEGF-R2; (pg/mL)	7998; (6335–10215)	8670; (5980–11980)	9033; (7491.75–11964.5)	10076; (6109–12973.5)	7536.5; (5479–9295)
Platelets; (10^9/L)	240; (192–316)	226; (187.0–267)	217; (186–254.75)	230; (212.5–265.5)	230.5; (190–251)

: number of patients; CSU: chronic spontaneous urticaria; DPU: delayed pressure urticaria; ASST: autologous serum skin test; IQR: interquartile range; : statistically significant values as compared with the control group.